+1 (202) 780-3397
Short Communication - Hematology and Blood Disorders (2020) Volume 3, Issue 1
Future prospects for DLBCL treatment: Combination of WEE1 inhibitors with CHOP and radiation therapy
Diffuse large B-cell lymphoma (DLBCL) is the most aggressive and common form of non-Hodgkin lymphoma. DLBCL arises during B-cell development in the germinal center reaction as a result of high levels of genomic rearrangements to create high affinity B-cell receptors. Therefore, an important hallmark of DLBCL is the high levels of genomic instability; DNA damage and DNA damage response proteins
Author(s): Tom van Meerten, Mathilde Rikje Willemijn de Jong, Lydia Visser